Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

HER2

5 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Jhaveri K, Eli LD, Hurvitz SA, et al.

Clinical cancer research

This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.

Clinical

Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study

Kang HJ, Kim M, Kwak YK, et al.

Medicine

This retrospective study investigated prognostic factors and outcomes of postmastectomy radiation therapy (PMRT) following neoadjuvant chemotherapy (NAC) and mastectomy for stage II-III breast cancer. It included 178 patients with a median follow-up of 64 months. The findings indicated that response to NAC, molecular subtype, and pathologic stage are independent predictors of treatment outcomes. PMRT did not offer significant benefits for patients with pathologically node-negative disease (ypN0) but significantly improved locoregional control, progression-free survival, and overall survival in those with residual lymph nodes (ypN1-3). Triple-negative subtype and non-response to NAC were identified as poor prognostic factors.

Clinical · Molecular biology · Bioinfo & AI

Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches

Yao J, Liu Z, Zhang J, et al.

International journal of clinical oncology

This study identified and functionally validated lipid droplet (LD)-associated prognostic biomarkers in breast cancer through integrative multi-omics and machine learning. A prognostic model, built using the StepCox[both]+plsRcox algorithm, effectively stratified patients across molecular subtypes, outperforming traditional ER/PR/HER2 status. Key genes, SQLE and SOCS3, were identified with opposing roles: SQLE promoting adipogenesis and SOCS3 inhibiting it, influencing the tumor microenvironment and immune infiltration. Modulating these genes suppressed tumor growth and polarized macrophages towards an M1 phenotype, highlighting their potential as therapeutic targets.

Clinical

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer

Weiner-Gorzel K, McSorley L, Walshe JM

Current treatment options in oncology

Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.

Molecular biology

Multimodal molecular profiling of invasive ductal carcinoma: High concordance of qPCR with FISH in HER2 assessment and exomic landscape of high-risk subtypes

Balar S, Joshi E, Rawal R, et al.

Pathology, research and practice

This study evaluates the efficacy of qPCR for HER2 status assessment in invasive ductal carcinoma of the breast, comparing it with IHC and FISH. Results demonstrate high concordance between qPCR and FISH, particularly in resolving equivocal IHC 2+ cases. Furthermore, exploratory genomic profiling via WES on high-risk subtypes (HER2 3+ and TNBC) revealed somatic mutations in key genes such as TP53, BRCA1, and MYCN, as well as AR expression in TNBC. These findings highlight qPCR’s potential as an accurate diagnostic tool and provide a foundation for future precision oncology strategies.